A study shows that the monthly production cost of semaglutide, the active ingredient in Ozempic and Wegovy, could be as low as $3. Simultaneously, the manufacturer, Novo Nordisk, announced price reductions for its products in Spain to improve patient access to therapy. A Polish portal mentions potential costs of 11 PLN for monthly injections and 59 PLN for tablets, though this most likely refers to hypothetical future generic prices, not a current market offer. The information indicates growing price pressure in the diabetes and obesity drug segment.
Potential Production Cost of $3
An independent study, reported by Bloomberg and The Guardian, indicates that the monthly cost of producing semaglutide could be as low as about $3, which stands in stark contrast to the current high retail prices.
Price Reduction in Spain
The company Novo Nordisk, manufacturer of Ozempic and Wegovy, announced a voluntary price reduction for its drugs in Spain. This aims to facilitate access to therapy for patients with type 2 diabetes and obesity.
Prospect of Cheap Generics
The study emphasizes that after patents expire, the emergence of cheap generic drugs, i.e., substitutes, could radically lower treatment costs for healthcare systems and patients worldwide.
Polish Speculation About Low Prices
The Polish portal telepolis.pl reports information about a possible price for Ozempic at 11 PLN monthly for injections and 59 PLN for tablets. However, this is a report referring to future, hypothetical prices, not the current availability of the drug in Poland.
Price pressure is mounting on the global pharmaceutical market for breakthrough diabetes and obesity drugs like Ozempic and Wegovy. Two independent sources – Bloomberg Business and The Guardian – cite a study indicating that the monthly production cost of the active ingredient, semaglutide, could be as low as about $3. This discovery calls into question the justification for the currently very high retail prices of these drugs, which in many countries represent a significant burden for patient budgets and healthcare systems. Researchers emphasize that after Novo Nordisk's patents expire, the emergence of cheap generic drugs, i.e., substitutes with identical composition, could revolutionize treatment accessibility. Semaglutide belongs to the class of GLP-1 analog drugs. Its invention and commercialization by the Danish company Novo Nordisk in the second decade of the 21st century are considered one of the greatest successes of modern pharmacology, bringing the company billions in revenue. Parallel to these analyses, the drug manufacturer, Novo Nordisk, has taken concrete action. According to reports from the Spanish newspapers "La Razón" and "EL MUNDO," the corporation announced a voluntary price reduction for Ozempic and Wegovy in the Spanish market. The decision aims to facilitate access to treatment for patients with type 2 diabetes and obesity. This is a response to the broad discussion regarding the high costs of these therapies and pressure from various stakeholders, including payers. These reports show that pressure for price reductions is not just theoretical but translates into real business decisions in individual countries.
The Polish portal telepolis.pl goes even further in price speculation in its article, writing about "Ozempic for 11 PLN monthly in injections and 59 PLN in tablets." However, this should be treated as information referring to potential future generic prices, not as a current market offer. In Poland, as in many other countries, the original Ozempic remains a reimbursed drug for specific indications, and its retail price outside reimbursement is significantly higher. The portal likely extrapolates the results of the mentioned study onto a hypothetical scenario of a cheap Polish substitute appearing. „Ozempic for 11 PLN monthly in injections and 59 PLN in tablets.” (telepolis.pl) — The title of the portal telepolis.pl suggests that the drug Ozempic is already available for the stated amounts. In reality, this is speculation based on a study concerning potential future generic production costs. Currently, the retail price of the original drug in Poland is many times higher, and the information may mislead readers about the current availability and costs of therapy. This entire situation perfectly illustrates the tension between innovation and accessibility in pharmaceuticals. On one hand, pharmaceutical companies must recoup enormous research and development investments; on the other – societies and healthcare systems demand access to effective therapies at affordable prices. The impending patent expirations and potential influx of generics could be a key moment of change in this market.